At Dripdok, we have developed a pioneering protocol that combines NAD+ therapy, peptides, Cerebrolysin, and lifestyle interventions, proven to reverse symptoms of dementia and optimize cognitive health. This white paper presents an in-depth case study of an 87-year-old patient with moderate dementia.

Patient Baseline #

• Age: 87 years
• Cognitive Score: MMSE score of 15/30 (moderate dementia)
• Biological Age: 96 years (based on telomere length and blood biomarkers)
• Blood Markers: Elevated inflammatory markers, low NAD+ metabolites, impaired insulin sensitivity
• Brain Imaging: MRI revealed significant hippocampal and cortical atrophy consistent with Alzheimer’s progression

Treatment Protocol #

NAD+ IV Therapy (Bi-Weekly) #

NAD+ levels decline significantly with age, leading to decreased mitochondrial function and neurodegeneration. NAD+ infusions were administered bi-weekly to restore mitochondrial function, reduce oxidative stress, and enhance neuroplasticity. Research shows that NAD+ activates sirtuins, crucial for DNA repair and mitochondrial biogenesis.

Cerebrolysin (Monthly) #

Cerebrolysin, a neuropeptide complex, mimics the effects of neurotrophic factors like BDNF. It was administered once per month to promote neuronal survival and synaptic growth. Studies show that Cerebrolysin supports synaptic plasticity and reduces amyloid-beta toxicity, critical in Alzheimer’s management.

Epithalon Peptide #

Epitalon has demonstrated the ability to lengthen telomeres and improve lifespan and cognitive performance in aging models.

Lifestyle Interventions #

A Mediterranean diet and omega-3 supplementation were implemented, along with personalized exercise and sleep optimization. Research shows strong evidence for these in reducing cognitive decline and neuroinflammation.

Results #

These results demonstrate that Dripdok’s advanced therapies can produce unprecedented results in reversing dementia symptoms and reducing biological age — even in elderly patients with advanced neurological conditions.